Survival outcome of chemotherapy in stage IIIA and IIIB non-small cell lung cancer

被引：0
|
作者：
Aly, A. S. E. S. [1 ]
Ellaithy, A. [1 ]
机构：
[1] Suez Canal Univ Hosp, Ismailia, Egypt
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
116P
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [41] Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer
    Jang, Seung Hun
    Park, Sojung
    Lee, Chang Youl
    Park, Ji Young
    Kim, Joo-Hee
    Park, Sunghoon
    Hwang, Yong Il
    Jung, Ki-Suck
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [42] Pathologic response and resectability after combined modality treatment for stage IIIA & IIIB non-small cell lung cancer
    Pisch, J
    Malamud, S
    Yudelman, I
    Ross, D
    Keller, S
    [J]. 3RD INTERNATIONAL CONGRESS ON LUNG CANCER, 1998, : 279 - 283
  • [43] Advanced radiotherapy techniques in stage IIIB non-small cell lung cancer
    Price, Allan
    Reilly, Andrew
    Erridge, Sara C.
    [J]. EJC SUPPLEMENTS, 2007, 5 (05): : 269 - 276
  • [44] Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer
    Liang, Hengrui
    Deng, Hongsheng
    Liang, Wenhua
    Guo, Kai
    Gao, Ziqing
    Wiesel, Ory
    Flores, Raja M.
    Song, Kimberly
    Redwan, Bassam
    Migliore, Marcello
    Li, Shuben
    Yin, Weiqiang
    He, Jianxing
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (05)
  • [45] The role of surgery in the treatment of stage IIIB non-small cell lung cancer
    Grunenwald, Dominique H.
    [J]. EJC SUPPLEMENTS, 2007, 5 (05): : 263 - 267
  • [46] Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study
    Cai, Guoxin
    Wang, Kaiyue
    Wang, Xiaohan
    Zhao, Jiarui
    Han, Xiao
    Zhou, Haiyan
    Xie, Chao
    Jia, Hui
    Fu, Shuai
    Huang, Yong
    Li, Wanhu
    Teng, Feifei
    Wang, Suzhen
    Yu, Jinming
    Song, Pingping
    Meng, Xue
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC)
    Wang, Ting
    Huang, Lu Li Lin
    Liu, Jie Wei
    Zhu, Da Xing
    Dong, Jing Si
    Deng, Han Yu
    Zheng, Xi
    Tian, Long
    Jiang, Li Li
    Wang, Wei Ya
    Zhou, Ping
    Su, Ming Gang
    Pu, Dan
    Cai, Xu Yu
    Feng, Ming Yang
    Ou, Xue Jin
    Wang, Yongsheng
    Zhou, Qing Hua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Survival of Patients with Unsuspected N2 (Stage IIIA) Non-Small Cell Lung Cancer
    Yamamichi, Takashi
    Harada, Masahiko
    Hishima, Tsunekazu
    Asakawa, Ayaka
    Okui, Masayuki
    Horio, Hirotoshi
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S768 - S768
  • [49] Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
    Kuo, SH
    Yang, CH
    Yu, CJ
    Hsu, C
    Cheng, AL
    Yang, PC
    [J]. LUNG CANCER, 2005, 48 (02) : 275 - 280
  • [50] SURVIVAL OF PATIENTS WITH UNSUSPECTED N2 (STAGE IIIA) NON-SMALL CELL LUNG CANCER
    Park, Chang Kwon
    Lee, Deok Heon
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S883 - S883
12345